Documents

Filter documents Clear search

pdf icon

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

pdf icon

FSRH CEU Statement: Response to recently published “Bridge-It” study by Cameron, et al - November 2020

File size: 209kb | Date: 23 November 2020 | Clinical Statements - PDF

The FSRH CEU summarizes and comments on the Cameron, et al “Bridge-It” study, which found that women receiving levonorgestrel emergency contraception from a pharmacy are more likely to be using effective ongoing contraception if they are given a three-month supply of progestogen-only pill and facilitated access to local SRH services.

pdf icon

FSRH CEU Statement: Response to Recent Publication Regarding Banh, et al - November 2020

File size: 233kb | Date: 17 November 2020 | Clinical Statements - PDF

“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg” The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.

pdf icon

FSRH CEU recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions

File size: 396kb | Date: 20 March 2020 | Clinical Statements - PDF

At present, to reduce risk of coronavirus transmission, non-essential face-to-face contact with healthcare providers is being minimised where possible. Replacement procedures for long-acting reversible contraceptive (LARC) devices that have recently expired are non-essential. This FSRH CEU statement provides recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions.

pdf icon

FSRH CEU clinical advice to support provision of effective contraception during the COVID-19 outbreak

File size: 402kb | Date: 20 March 2020 | Clinical Statements - PDF

During Covid19-related restriction in face-to-face contact with healthcare professionals, FSRH CEU offers the following clinical advice to support ongoing provision of effective contraception. Provision of effective contraception (this may be a bridging method in the short term) and emergency contraception are considered priority services.

pdf icon

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

File size: 206kb | Date: 12 August 2019 | Clinical Statements - PDF

This statement reviews and summarises the available evidence regarding the effect of contraception on weight. Looking at each method individually, the FSRH CEU advises clinicians regarding proven and theoretical associations between contraceptive options and weight/BMI.